Carlos F. Sánchez-Ferrer

He leads a UAM and IdiPAZ research group named with the acronym FARMAVASM, dedicated to the study of the mechanisms that produce deterioration of the vascular function in pathological conditions.

María Trinidad Herrero Ezquerro

Professor of Human Anatomy at the Faculty of Medicine of the University of Murcia. Director of the Official Aging Research Institute of Murcia.

Marc Ramis

He is a co-founder and CEO at Senolytic Therapeutics Inc., a pharmaceutical company that develops a novel class of medicines by targeting senescence cells. He is also supporting investments and strategic partnerships at Life Biosciences Inc. in Europe.

Manuel Serrano

Manuel Serrano obtained his PhD in 1991, from the Universidad Autónoma de Madrid. From 1991 to 1996, Serrano worked in the team of David Beach in Cold Spring Harbor Laboratory, NY. During this period, Serrano made his most important discovery with the identification and characterization of the gene p16.

Manuel Collado

Manuel Collado holds a PhD in Biology from the Universidad Autónoma de Madrid. Having previously worked in London, New York and at the Spanish National Cancer Research Centre (CNIO) in Madrid, he is currently at the Health Research Institute of Santiago de Compostela (IDIS).

Manuel Serrano: “I don’t know how to use the word immortality. I don’t see any point in talking about something so intangible”

Manuel Serrano is internationally recognised in the field of tumour suppression. In addition to his discovery of the p16 gene, one of his most important discoveries has been the identification of cellular senescence as a main anti-oncogenic response. In this the second edition of Longevity World Forum, he will share his extensive experience, as well as the advances on which he is currently working at the Institute for Research in Biomedicine (IRB Barcelona).